Hostname: page-component-7b7567c8c-m6dxt Total loading time: 0 Render date: 2026-11-19T05:08:19.956Z Has data issue: false hasContentIssue false

Complementary medicines in psychiatry

Review of effectiveness and safety

Published online by Cambridge University Press:  02 January 2018

Ursula Werneke*
Affiliation:
Division of Health Service Research, Institute of Psychiatry, and Division of Psychiatry Homerton University Hospital
Trevor Turner
Affiliation:
Division of Psychiatry, Homerton University Hospital
Stefan Priebe
Affiliation:
Unit for Social and Community Psychiatry, Barts and The London, NHS Trust, Queen Mary School of Medicine and Dentistry, London, UK
*
Dr Ursula Werneke, Division of Psychiatry, HomertonUniversity Hospital, East Wing, Homerton Row, London E9 6SR, UK. E-mail: UrsulaWerneke@elcmht.nhs.uk
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Background

The use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed.

Aims

To review the complementary medicines routinely encountered in psychiatric practice, their effectiveness, potential adverse effects and interactions.

Method

Electronic and manual literature search on the effectiveness and safety of psychotropic complementary medicines.

Results

Potentially useful substances include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as sedatives, St John's wort and sadenosylmethionine as antidepressants, and selenium and folate to complement antidepressants. The evidence is less conclusive for the use of omega-3 fatty acids as augmentation treatment in schizophrenia, melatonin for tardive dyskinesia and 18-methoxycoronaridine, an ibogaine derivative, for the treatment of cocaine and heroin addiction.

Conclusions

Systematic clinical trials are needed to test promising substances. Meanwhile, those wishing to take psychotropic complementary medicines require appropriate advice.

Information

Type
Review Article
Copyright
Copyright © 2006 The Royal College of Psychiatrists 

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.